The basic accounting equation is
Liabilities = Assets – Owners Equity
Cash is just one asset. It's always nice when a company is sitting on a pile of it the way Apple and Esperion Therapeutics are - though, of course, those two operate on vastly different scales and I'm not suggesting that they're much alike.
My statement about SE was supposed to convey my impression that the company is in a tailspin with no strong support in sight. Based only on a quick TA analysis, there's no reason to recommend it.
I sometimes find stocks that have fundamental (not technical) reasons for optimism. For instance, the other day I read about a one-trick-pony that had everything invested in a drug that the FDA had just nixed. That was horrible news, and the stock fell 80% in after-hours trading. TA said to stay clear of it. However, the company actually had cash on its books that exceeded its market cap by a wide margin, and it was worth buying if only to get a stake in parting the company out.
So that's what I meant about SE. If it's sitting on a mountain of cash that investors are forgetting about, then it might still be a good investment. From what I could see, though, it looks like a stock that's going to continue falling for quite some time. SE is currently $23/share. $13/share looks possible this time next year.